Search results for "alcoholic"

showing 10 items of 509 documents

Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.

2015

Background & Aims The pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD) is still incompletely understood. Several nuclear receptors play a role in liver lipid metabolism and can promote hepatosteatosis, but the possible role of vitamin D receptor (VDR) in NAFLD has not been investigated. Methods The expression of liver VDR was investigated in apolipoprotein E knockout ( apoE −/− ) mice on a high fat diet, in wild-type mice on methionine and choline deficient diet and in NAFLD patients with hepatosteatosis and non-alcoholic steatohepatitis. The relevance of VDR was assessed in apoE −/− mice by deletion of VDR or paricalcitol treatment and in human HepG2 cells by VDR t…

0301 basic medicineApolipoprotein Emedicine.medical_specialtyCD36Retinoid X receptorDiet High-FatCalcitriol receptor03 medical and health sciencesMiceNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineAnimalsHumansHepatologybiologyFatty liverLipid metabolismmedicine.diseaseLipid MetabolismMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyLiverbiology.proteinHepatocytesReceptors Calcitriollipids (amino acids peptides and proteins)SteatosisSteatohepatitisJournal of hepatology
researchProduct

LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics.

2018

High resolution LC-MS untargeted lipidomics using data independent acquisition (DIA) has the potential to increase lipidome coverage, as it enables the continuous and unbiased acquisition of all eluting ions. However, the loss of the link between the precursor and the product ions combined with the high dimensionality of DIA data sets hinder accurate feature annotation. Here, we present LipidMS, an R package aimed to confidently identify lipid species in untargeted LC-DIA-MS. To this end, LipidMS combines a coelution score, which links precursor and fragment ions with fragmentation and intensity rules. Depending on the MS evidence reached by the identification function survey, LipidMS provi…

0301 basic medicineChromatographyChemistry010401 analytical chemistryLipidomeMass spectrometry01 natural sciencesLipids0104 chemical sciencesAnalytical Chemistry03 medical and health sciencesR packageAnnotation030104 developmental biologyNon-alcoholic Fatty Liver DiseaseTandem Mass SpectrometryLipidomicsLipidomicsHumansData-independent acquisitionHigh dimensionalityData dependentBiomarkersDatabases ChemicalChromatography LiquidAnalytical chemistry
researchProduct

Copper/MYC/CTR1 interplay: A dangerous relationship in hepatocellular carcinoma

2018

Free serum copper correlates with tumor incidence and progression of human cancers, including hepatocellular carcinoma (HCC). Copper extracellular uptake is provided by the transporter CTR1, whose expression is regulated to avoid excessive intracellular copper entry. Inadequate copper serum concentration is involved in the pathogenesis of Non Alcoholic Fatty Liver Disease (NAFLD), which is becoming a major cause of liver damage progression and HCC incidence. Finally, MYC is over-expressed in most of HCCs and is a critical regulator of cellular growth, tumor invasion and metastasis. The purpose of our study was to understand if higher serum copper concentrations might be involved in the prog…

0301 basic medicineCirrhosisCopper; CTR1; Hepatocellular carcinoma; MYC; Non alcoholic fatty liver disease; OncologyMYCMetastasis03 medical and health sciencesmedicineOncogeneCell growthChemistryFatty liverCTR1hepatocellular carcinomaHCCSmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyOncologyHepatocellular carcinomacopperCancer researchCTR1; MYC; copper; hepatocellular carcinoma; non alcoholic fatty liver diseaseLiver cancerResearch Papernon alcoholic fatty liver disease
researchProduct

AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

2017

Abstract This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (…

0301 basic medicineDiagnostic ImagingLiver Cirrhosismedicine.medical_specialtyCirrhosisEpidemiologySettore MED/12 - GASTROENTEROLOGIAPhysiopathologyNatural historyType 2 diabetesDiseaseDiagnosis; Epidemiology; Genetics; Management; Natural history; PhysiopathologyBioinformaticsGastroenterology03 medical and health sciences0302 clinical medicineGeneticNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseDiagnosismedicineGeneticsHumansmedicine.diagnostic_testHepatologyDiagnosis; Epidemiology; Genetics; Management; Natural history; Physiopathology; Hepatology; Gastroenterologybusiness.industryLiver NeoplasmsGastroenterologyHepatologymedicine.diseaseManagement030104 developmental biologyLipotoxicityDiabetes Mellitus Type 2LiverCardiovascular DiseasesLiver biopsy030211 gastroenterology & hepatologySteatohepatitisbusinessBiomarkersDiagnosi
researchProduct

New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease

2017

Background and Aims: Drug-induced steatosis is a major reason for drug failure in clinical trials and post-marketing withdrawal; and therefore, predictive biomarkers are essential. These could be particularly relevant in non-alcoholic fatty liver disease (NAFLD), where most patients show features of the metabolic syndrome and are prescribed with combined chronic therapies, which can contribute to fatty liver. However, specific biomarkers to assess the contribution of drugs to NAFLD are lacking. We aimed to find microRNAs (miRNAs) responsive to steatotic drugs and to investigate if they could become circulating biomarkers for drug induced steatosis. Methods: Human HepG2 cells were treated wi…

0301 basic medicineDrugFarmacologiaMicroarraymedia_common.quotation_subjectBiologyPharmacology03 medical and health scienceshepatosteatosisCyclosporin amedicinePharmacology (medical)predictive biomarkermedia_commonOriginal ResearchPharmacologyFenofibratemicroRNAFatty livernon-alcoholic fatty liver diseasemedicine.diseasePatologiadrug-induced steatosis030104 developmental biologymetabolic syndrome drugDroguesSteatosisMetabolic syndromeTamoxifenmedicine.drugFrontiers in Pharmacology
researchProduct

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

2021

[Background and Aims] Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH).

0301 basic medicineFIBROSIS NONINVASIVE ASSESSMENTCirrhosisTransient elastographydeMILI0302 clinical medicineMedicineBARIATRIC SURGERY CANDIDATESNon-alcoholic steatohepatitismedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISFatty liverMagnetic Resonance Imaging3. Good healthArea Under CurveLiver biopsyElasticity Imaging TechniquesNASH-MRI030211 gastroenterology & hepatologyBio-markersRadiologyElastographyDiffusion-weighted imagingLife Sciences & BiomedicineAdultPREDICTS ADVANCED FIBROSISmedicine.medical_specialtyBiomarkers deMILI Diffusion-weighted imaging Magnetic resonance elastography NASH-MRI Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Shear wave elastography Transient elastography AdultArea Under Curve Elasticity Imaging Techniques Humans Magnetic Resonance Imaging Non-alcoholic Fatty Liver Disease ROC Curve fibro-MRI Iron-corrected T1 Liver fibrosisLiver fibrosisCONTROLLED ATTENUATION PARAMETERSTIFFNESS MEASUREMENT03 medical and health sciencesIron-corrected T1HumansFATTY LIVER-DISEASEScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryRADIATION FORCE IMPULSEMagnetic resonance imagingmedicine.diseaseCONTROLLED TRANSIENT ELASTOGRAPHYMagnetic resonance elastography030104 developmental biologyROC CurveMagnetic resonance elastographyShear wave elastographyXL PROBEHuman medicinefibro-MRISteatohepatitisbusinessTransient elastographyBiomarkersNon-alcoholic fatty liver diseaseJournal of Hepatology
researchProduct

Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease.

2021

BACKGROUND & AIMS: Fatty liver disease (FLD) is a growing epidemic that is expected to be the leading cause of end-stage liver disease within the next decade. Both environmental and genetic factors contribute to the susceptibility of FLD. Several genetic variants contributing to FLD have been identified in exome-wide association studies. However, there is still a missing hereditability indicating that other genetic variants are yet to be discovered. METHODS: To find genes involved in FLD, we first examined the association of missense and nonsense variants with alanine amino transferase at an exome-wide level in 425,671 participants from the UK Biobank. We then validated genetic variants wit…

0301 basic medicineGenome-wide association studyLiver disease0302 clinical medicineENRICHMENT ANALYSISNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseExomeCONFERS SUSCEPTIBILITYGeneticsINSULIN-RESISTANCEmedicine.diagnostic_testFatty liverGastroenterologyAlanine Transaminase1-Acylglycerol-3-Phosphate O-Acyltransferase3. Good healthGENOMEEuropePhenotypeLiver biopsy030211 gastroenterology & hepatologyNonalcoholic Fatty Liver DiseaseMAFLDSingle-nucleotide polymorphismBiologyTransaminaseRisk Assessment03 medical and health sciencesApolipoproteins ENAFLDmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseHEPATIC STEATOSISGenetic associationMAFLD Phenotype Reproducibility of Results Risk Assessment Risk Factors Transcriptome Genetic Variation Metabolic Associated Fatty Liver Disease Nonalcoholic Fatty Liver Disease Transaminase 1-Acylglycerol-3-Phosphate O-Acyltransferase Alanine Transaminase Apolipoproteins E Biomarkers Europe Exome Gene Expression Profiling Genetic Predisposition to Disease Genome-Wide Association Study Humans Non-alcoholic Fatty Liver DiseaseHepatologyMUTATIONSGene Expression ProfilingGenetic VariationReproducibility of Resultsmedicine.diseaseX-RECEPTORGENE030104 developmental biology3121 General medicine internal medicine and other clinical medicineMetabolic Associated Fatty Liver DiseaseRNA-SEQ DATATranscriptomePATHOGENICITYBiomarkersGenome-Wide Association StudyGastroenterology
researchProduct

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease

2017

Background and Aims: The IFNL3/4 locus influencing innate immunity regulation has been associated with the severity of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results were reported in NAFLD. In this study, we examined whether rs12979860 and the linked causal rs368234815 variant encoding for the alternative IFNL4 protein variant are associated with liver fibrosis and damage in a large multicenter cohort of patients at risk of NASH. To clarify the mechanism, we also evaluated the impact on interferon-stimulated gene (ISG) hepatic expression in a subset of patients. Methods: We considered 946 consecutive Italian individuals at risk of NASH wit…

0301 basic medicineHepatitismedicine.medical_specialtyNAFLD NASH IFNL4Hepatologybusiness.industryLocus (genetics)medicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineFibrosisInternal medicineNonalcoholic fatty liver diseaseCohortGenotypemedicine030211 gastroenterology & hepatologyAllelebusinessProspective cohort studyHepatology
researchProduct

FT-IR spectroscopy : A powerful tool for studying the inter- and intraspecific biodiversity of cultivable non-Saccharomyces yeasts isolated from grap…

2016

International audience; The efficiency of the FT-IR technique for studying the inter- and intra biodiversity of cultivable non-Saccharomyces yeasts (NS) present in different must samples was examined. In first, the capacity of the technique FF-IR to study the global diversity of a given sample was compared to the pyrosequencing method, used as a reference technique. Seven different genera (Aureobasidium, Candida, Cryptococcus, Hanseniaspora, Issatchenkia, Metschnikowia and Pichia) were identified by FT-IR and also by pyrosequencing. Thirty-eight other genera were identified by pyrosequencing, but together they represented less than 6% of the average total population of 6 musts. Among the sp…

0301 basic medicineIdentification[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionBiodiversityWineHanseniasporaSaccharomycesMicrobial ecology[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyYeastsSpectroscopy Fourier Transform InfraredVitisDNA FungalMycological Typing TechniquesPhylogenyCandidaIntragenomic variationbiologySp-nov.Pyrolysis mass-spectrometryPyrosequencingBiodiversityCandida zemplininaYeast in winemaking[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyFT-IR spectroscopyMetschnikowiaAlcoholic fermentationMicrobiology (medical)food.ingredientWine yeast030106 microbiologyMicrobiologyIntraspecific competitionCandida-zemplininaSaccharomyces03 medical and health sciencesfoodBotanyRNA Ribosomal 18SMolecular BiologyBase SequenceComputational BiologySequence Analysis DNAbiology.organism_classificationGreen lacewingsStrain typingPyrosequencingTransform-infrared-spectroscopy[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBotrytis-affected wine
researchProduct

Pathophysiology of non alcoholic fatty liver disease

2016

The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style and inflammation, which have a major impact on the severity of the clinicopathologic outcome of non-alcoholic fatty liver disease. A short comprehensive review is provided on current knowledge of the pathophysiological interplay among major circulating effectors/mediators of fatty liver, such as circulating lipids, mediators released by adipose, muscle and liver tissues and pancreatic and gut hormones in relation to diet, exercise and inflammation.

0301 basic medicineLeptinAdipose tissueReviewDiseaseCatalysilcsh:Chemistry0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInsulinAdiponectin; Cholesterol; Fatty liver; Free fatty acids; Ghrelin; Glucagon; Glucagon-like peptide 1; Insulin; Insulin resistance; Irisin; Leptin; Selenoprotein P; Adipose Tissue; Gastrointestinal Hormones; Humans; Lipids; Muscles; Non-alcoholic Fatty Liver Disease; Pancreatic Hormones; Catalysis; Molecular Biology; Computer Science Applications1707 Computer Vision and Pattern Recognition; Spectroscopy; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic Chemistrylcsh:QH301-705.5SpectroscopyGastrointestinal HormoneFree fatty acidMusclesFatty liverComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineLipidLipidsPathophysiologyGhrelinComputer Science ApplicationsCholesterolAdipose TissueMuscleAdiponectinmedicine.symptomHumanmedicine.medical_specialtyIrisinSettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismInflammationBiologyFree fatty acidsCatalysisPancreatic HormoneGastrointestinal HormonesInorganic Chemistry03 medical and health sciencesInternal medicineFatty liverSelenoprotein PmedicineHumansPhysical and Theoretical ChemistryGlucagon-like peptide 1Molecular BiologyOrganic ChemistryNon alcoholicInsulin resistancemedicine.diseaseGut hormonesGlucagonPancreatic Hormones030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999Metabolic syndrome
researchProduct